Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 587

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Circulating miRNAs are correlated with tumor progression in prostate cancer

Open access
Brase, Jan C., Johannes, Marc, Schlomm, Thorsten, Fälth, Maria, Haese, Alexander, Steuber, Thomas, Beissbarth, Tim, Kuner, Ruprecht, Sültmann, Holger·2011·International Journal of Cancer

Abstract

Circulating miRNAs have recently been indicated as practicable and promising biomarkers for noninvasive diagnosis in various tumor entities. However, cell‐free miRNAs have not been found to correlate with clinicopathological variables in epithelial carcinomas. To learn more about the potential clinical relevance of circulating miRNAs in prostate cancer, we screened 667 miRNAs in serum samples from patients with metastatic (n= 7) and localized prostate cancer (n= 14). Various miRNAs were highly abundant in the sera of patients with metastatic disease, and five upregulated miRNAs (miRNA‐375, miRNA‐9*, miRNA‐141, miRNA‐200b and miRNA‐516a‐3p) were selected for further validation. In the first validation study (n= 45), selected miRNAs were analyzed in a prospectively collected serum set taken from different prostate cancer risk groups. Most of the selected miRNAs were significantly correlated with adverse risk factors when different clinicopathological variables were analyzed. Circulating miRNA‐375 and miRNA‐141 turned out to be the most pronounced markers for high‐risk tumors. Their levels also correlated with high Gleason score or lymph‐node positive status in a second independent validation study (n= 71). In addition, the expression levels of miRNA‐375 and miRNA‐141 were monitored in 72 prostate tissue samples (36 tumor vs. 36 benign). Both miRNAs were highly expressed in all samples and significantly upregulated in the tumors compared to normal tissues. Overall, our observations suggest that miRNA‐375 and miRNA‐141 expression is enhanced in prostate cancer specimens and their release into the blood is further associated with advanced cancer disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.25376

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 587

Metadata

Authors
Brase, J. C., Johannes, M., Schlomm, T., Fälth, M., Haese, A., Steuber, T., Beissbarth, T., Kuner, R., & Sültmann, H.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2010-11-27
Volume
128
Issue
3
Pages
608-616
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2022667041
Cited by
587
References
8
FWCI
13.19
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating miRNAs are correlated with tumor progression in prostate cancer. https://app.cochat.ai/papers/10.1002/ijc.25376
The paper
Brase, J. C., Johannes, M., Schlomm, T., Fälth, M., Haese, A., Steuber, T., Beissbarth, T., Kuner, R., & Sültmann, H. (2011). Circulating miRNAs are correlated with tumor progression in prostate cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.25376

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.